Abstract： Objective To explore the clinical effectiveness intravenous immunoglobulin therapy for kidney transplant recipients with acute humoral rejection of the clinical effects.Methods From January 2005 to December 2007,252 cases received kidney transplantation,and according to the standard of Banff,there were 16 cases of acute humoral rejection(3 cases of grade I,9 cases of grade Ⅱ,and 4 cases of grade Ⅲ).Tacrolimus,mycophenolate mofetil and corticosteroids were used to prevent rejection,16 AHR patients were treated with intravenous immunoglobulin(IVIG)treatment,20 g/d for 3 d.12 patients whose AHR occurred withing 1 month delayed graft function,so they had hemodialysis transition,amd 1 case of them had plasma exchange treatment.The reversal of AHR and the changes in humoral and cellular immunity of recipients were observed.Results 13 cases was reversed and 3 cases had nephrectomy.After treatment,the differents of reduction level in HLA-I and HLA-Ⅱantibody was not obvious(P>0.05).The IgG level was increased from(7.3±1.5)g/L to (18.3±3.6)g/L,significantly(P<0.01).After treatment,C3 and C4 levels were reduced tO(0.3± 0.2)g/L and(0.1±0.1)g/L,significantly(P<0.01).During treatment,2 cases occurred chest discomfort and fever.Patientsliver function had no significant difference after treatment.Conclusion IVIG in the early treatment of kidney transplant recipients with AHR had a certain effect,the mechanism might be antibody-blocked,as well as humoral and cellular immunity regulation in patients.